United States of AmericaTuberculosis profile
Population  2015 322 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.59 (0.58–0.59) 0.18 (0.18–0.18)
Mortality (HIV+TB only) 0.077 (<0.01–0.38) 0.02 (0–0.12)
Incidence  (includes HIV+TB) 10 (8.9–12) 3.2 (2.8–3.7)
Incidence (HIV+TB only) 0.58 (0.49–0.67) 0.18 (0.15–0.21)
Incidence (MDR/RR-TB)** 0.18 (0.14–0.23) 0.06 (0.04–0.07)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.37 (0.2–0.53) 3.9 (2.8–4.9) 4.2 (3–5.5)
Males 0.35 (0.23–0.48) 5.8 (4.6–7.1) 6.2 (4.8–7.6)
Total 0.72 (0.51–0.93) 9.7 (8.8–11) 10 (8.9–12)
TB case notifications, 2015  
Total cases notified 9 551
Total new and relapse 9 058
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 93%
          - % pulmonary 79%
          - % bacteriologically confirmed among pulmonary 83%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.06 (0.04–0.09)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 465 6%
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  130
(110–160)
Estimated % of TB cases with MDR/RR-TB 1.5% (1.2–1.8) 5.5% (3.2–8.8)  
% notified tested for rifampicin resistance 76% 65% 7 227
MDR/RR-TB cases tested for resistance to second-line drugs   82
Laboratory-confirmed cases MDR/RR-TB: 109, XDR-TB: 1
Patients started on treatment **** MDR/RR-TB: , XDR-TB:
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 85% 8 237
Previously treated cases, excluding relapse, registered in 2014 79% 397
HIV-positive TB cases, all types, registered in 2014 80% 467
MDR/RR-TB cases started on second-line treatment in 2013 79% 39
XDR-TB cases started on second-line treatment in 2013 100% 1
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 142
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-06 Data: www.who.int/tb/data